tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

Revive Therapeutics Extends Private Placement to Support Therapeutic Programs
Company AnnouncementsRevive Therapeutics Extends Private Placement to Support Therapeutic Programs
2d ago
Revive Therapeutics Completes First Tranche of Private Placement and Debt Settlement
PremiumCompany Announcements
Revive Therapeutics Completes First Tranche of Private Placement and Debt Settlement
27d ago
Revive Therapeutics Announces Private Placement and Debt Settlement Plan
PremiumCompany Announcements
Revive Therapeutics Announces Private Placement and Debt Settlement Plan
1M ago
Revive Therapeutics Updates on Nerve Agent Countermeasure Study
PremiumCompany Announcements
Revive Therapeutics Updates on Nerve Agent Countermeasure Study
2M ago
Revive Therapeutics Advances Nerve Agent Countermeasure Study with Canadian Defence
PremiumCompany Announcements
Revive Therapeutics Advances Nerve Agent Countermeasure Study with Canadian Defence
2M ago
Revive Therapeutics nears completion of nerve agent countermeasure study
PremiumThe FlyRevive Therapeutics nears completion of nerve agent countermeasure study
2M ago
Revive Therapeutics Advances Next-Gen Bucillamine for Critical Medical Needs
Premium
Company Announcements
Revive Therapeutics Advances Next-Gen Bucillamine for Critical Medical Needs
3M ago
Revive Therapeutics Advances Bucillamine Research for Nerve Agent Exposure
Premium
Company Announcements
Revive Therapeutics Advances Bucillamine Research for Nerve Agent Exposure
4M ago
Revive Therapeutics Announces Shares for Debt Transaction to Preserve Cash
PremiumCompany Announcements
Revive Therapeutics Announces Shares for Debt Transaction to Preserve Cash
5M ago
Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial
PremiumThe Fly
Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial
5M ago
ATAI
CMND
Revive Therapeutics Explores Bucillamine’s Role in Cancer Treatment
PremiumCompany Announcements
Revive Therapeutics Explores Bucillamine’s Role in Cancer Treatment
5M ago
Revive Therapeutics to investigate Bucillamine’s potential in cancer treatment
PremiumThe Fly
Revive Therapeutics to investigate Bucillamine’s potential in cancer treatment
5M ago
Revive Therapeutics Expands Pipeline with Molecular Hydrogen Acquisition
PremiumCompany AnnouncementsRevive Therapeutics Expands Pipeline with Molecular Hydrogen Acquisition
5M ago
Revive enters asset purchase agreement for molecular hydrogen program
Premium
The Fly
Revive enters asset purchase agreement for molecular hydrogen program
5M ago
Revive Therapeutics Aligns with Shareholders in Annual Meeting Decisions
Premium
Company Announcements
Revive Therapeutics Aligns with Shareholders in Annual Meeting Decisions
6M ago
Revive Therapeutics announces results of annual shareholder meeting
PremiumThe Fly
Revive Therapeutics announces results of annual shareholder meeting
6M ago
Revive Therapeutics to Acquire DiagnaMed’s Molecular Hydrogen Program for Neurological Treatments
PremiumCompany Announcements
Revive Therapeutics to Acquire DiagnaMed’s Molecular Hydrogen Program for Neurological Treatments
6M ago
Revive Therapeutics enters LOI to acquire DiagnaMed’s molecular hydrogen program
PremiumThe Fly
Revive Therapeutics enters LOI to acquire DiagnaMed’s molecular hydrogen program
6M ago
Revive Therapeutics Advances Bucillamine Research for Nerve Agents and Long COVID
PremiumCompany Announcements
Revive Therapeutics Advances Bucillamine Research for Nerve Agents and Long COVID
7M ago
Revive Therapeutics Advances Research on Bucillamine for Nerve Agent Exposure
PremiumCompany AnnouncementsRevive Therapeutics Advances Research on Bucillamine for Nerve Agent Exposure
8M ago
Revive Therapeutics provides update on research study of bucillamine
Premium
The Fly
Revive Therapeutics provides update on research study of bucillamine
8M ago
Revive Therapeutics announces publication on potential of psilocybin
Premium
The Fly
Revive Therapeutics announces publication on potential of psilocybin
10M ago

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >